Stratosvir
Develops engineered viral immunotherapies for solid tumours and their metastases, aiming at cancer patients
Highlights
- New on EvolcAdded 2026-11-13
About Stratosvir
Stratosvir is developing viral immunotherapy for cancer. Its approach uses viruses engineered to replicate selectively in tumours, destroy malignant cells and reprogram the immune system against a broad range of solid tumours. The company's platform is designed to enable systemic delivery of therapeutic viruses, which are currently limited to intratumoral injection.
Stratosvir's stated aim is to offer cancer patients effective, non-toxic treatments that improve quality of life and survival. The company has received investment from Proven Connect (Prostate Cancer Research) and from UK cancer organisations, and an Innovate UK UK-Germany bilateral collaborative R&D grant.
Stratosvir Limited was founded in 2020 and is registered in England and Wales, with its registered office in Ingatestone. It also lists an address at the Stevenage Bioscience Catalyst in Hertfordshire. Its leadership includes Dr Chris Ullman (CEO), Antonio Postigo (CSO) and Priya Mande (Chairman).
Product: Engineered oncolytic viral immunotherapy platform for solid tumours, designed for systemic delivery
Jobs at Stratosvir
More biotech & pharma companies
Stream Bio
Develops and manufactures fluorescent bioimaging probes for life science research, diagnostics and therapeutic researchNew on EvolcSulantrix
Small-molecule drug discovery targeting pseudokinase ("zombie" protein) classes for hard-to-treat diseasesYoung companyNew on EvolcSuper B Plus Group
Pharmaceutical and medical device sourcing and wholesale supply for UK pharmacies, NHS Trusts and clinical trial sponsorsNew on EvolcSurescreen Scientifics
EDNA and molecular species identification lab testing samples for the UK ecology and planning sectorSygnature Discovery
Contract drug discovery services for biotech and pharma partners in the US, Canada, UK and EuropeSynaptixbio
Developing gene-silencing therapies for children with rare leukodystrophies, including H-ABCNew on Evolc
Website technologies
Tools and platforms detected on this company’s website, grouped by purpose. Dates record when Evolc observed them.
Content delivery
- CloudflareHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Response headerserver
- Response headerserver
Content management
- WordPressHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Frontend frameworks
- jQueryHigh confidence
- First detected
- Last detected
- Last checked
Detection evidence
- Website resourcedeclared script/iframe or software asset
Website detection does not establish a paid subscription or company-wide use. Tools loaded after consent or sign-in may be missed. “No longer observed” does not prove the company stopped using a tool.